![]() | ![]() |
Formats:
|
||||||||||||||||
Copyright © 2008 The Royal Society The evolution of RNAi as a defence against viruses and transposable elements 1Institute of Evolutionary Biology, School of Biological Sciences, The University of Edinburgh, Ashworth Laboratories, The King's Buildings, Edinburgh EH9 3JT, UK 2CSIRO Entomology, GPO Box 1700, Canberra ACT 2601, Australia 3Division of Pathway Medicine and Centre for Infectious Diseases, University of Edinburgh Medical School, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK *Author for correspondence (Email: darren.obbard/at/ed.ac.uk) This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This article has been cited by other articles in PMC.Abstract RNA interference (RNAi) is an important defence against viruses and transposable elements (TEs). RNAi not only protects against viruses by degrading viral RNA, but hosts and viruses can also use RNAi to manipulate each other's gene expression, and hosts can encode microRNAs that target viral sequences. In response, viruses have evolved a myriad of adaptations to suppress and evade RNAi. RNAi can also protect cells against TEs, both by degrading TE transcripts and by preventing TE expression through heterochromatin formation. The aim of our review is to summarize and evaluate the current data on the evolution of these RNAi defence mechanisms. To this end, we also extend a previous analysis of the evolution of genes of the RNAi pathways. Strikingly, we find that antiviral RNAi genes, anti-TE RNAi genes and viral suppressors of RNAi all evolve rapidly, suggestive of an evolutionary arms race between hosts and parasites. Over longer time scales, key RNAi genes are repeatedly duplicated or lost across the metazoan phylogeny, with important implications for RNAi as an immune defence. Keywords: antiviral RNAi, viral suppressors of RNAi, host–parasite coevolution, miRNA, piRNA, transposable element 1. Introduction Broadly defined, RNA interference (RNAi) constitutes a class of processes that use short RNAs (approx. 20–30 nucleotides) to recognize and manipulate complementary nucleic acids. RNAi-related pathways have roles in the control of gene expression, epigenetic modification and regulation of heterochromatin, and in the host–parasite interactions (see §2 for references). RNAi-related phenomena are so pervasive that it now seems surprising that the molecular basis of RNAi was first reported little more than 15 years ago (more that 97% of papers using the terms ‘RNAi’ and ‘RNA silencing’ have been published since 2001; for a historical perspective see Matranga & Zamore 2007). From a host–parasite and host–pathogen viewpoint, RNAi-related pathways provide a particularly interesting arena for coevolutionary interaction. For the host, RNAi is a defence against both viruses and ‘genomic parasites’ such as transposable elements (TEs), and can provide fine control over other components of innate immunity by modulating gene expression (Welker et al. 2007; Lodish et al. 2008). For the parasite, host RNAi can be exploited to subvert host cell function by manipulating host gene expression and blocking host resistance mechanisms. Strikingly, components of RNAi are widely distributed across the eukaryotic phylogeny, implying that the common ancestor of all eukaryotes had a functional RNAi pathway (Cerutti & Casas-Mollano 2006), over a billion years or more ago (Roger & Hug 2006). Immune system genes and the parasite molecules they interact with often evolve rapidly (Schlenke & Begun 2003). It is thought that this results from a coevolutionary arms race, in which there is a reciprocal process of adaptation and counteradaptation between parasites and hosts (Dawkins & Krebs 1979). As RNAi is a primary defence of many organisms against viruses and TEs, it is likely to be a key battlefield on which these arms races are played out. This has the potential to drive the rapid evolution of the proteins involved, and ultimately shape the RNAi pathways themselves (Obbard et al. 2006; Aravin et al. 2007; Marques & Carthew 2007). The major RNAi mechanisms have been recently reviewed (see §2) and it is not our purpose to duplicate that effort here. Instead, following a brief outline of the pathways most relevant to host–parasite biology, we review RNAi-mediated host–parasite interactions from an evolutionary perspective. We also present new analyses of the distribution of key RNAi-pathway genes across the animal phylogeny, and the rates of evolution in both RNAi genes and viral genes that suppress RNAi. 2. RNAi mechanisms that mediate host–parasite interactions The RNAi-related pathways are unified by their dependence on sequence-specific binding between short (approx. 20–30 nt) RNAs and target sequences, and their common use of Argonaute family proteins. However, this belies an enormous underlying diversity between pathways and phylogenetic lineages. For example, the short RNA molecules can be derived from exogenous double-stranded RNA (dsRNA) (including viral genomes and replicative intermediates), fold-back RNAs expressed by the host or virus, or overlapping pairs of sense and antisense transcripts. Different pathways also use different complements of Dicer, Argonaute and accessory proteins, and the outcome of RNAi can be the cleavage and degradation of target RNA, the recruitment of additional factors to modify gene expression, or even long-term expression changes through epigenetic modification and heterochromatin formation. (For recent reviews see Aravin et al. 2007; Chapman & Carrington 2007; Ding & Voinnet 2007; Hartig et al. 2007; Matranga & Zamore 2007; Slotkin & Martienssen 2007; Zaratiegui et al. 2007; Klattenhoff & Theurkauf 2008). For a glossary of relevant terms see table 1.
(a) The viRNA pathway The best-studied role of RNAi in the immune system is as a direct defence against viruses (figure 1
In addition to this core siRNA pathway (figure 1 In plants and nematodes, RNAi initiated in one cell can be propagated to neighbouring cells, and even to more distant tissues (‘non-cell-autonomous RNAi’; Jose & Hunter 2007). In C. elegans, the movement of siRNAs between cells depends on SID-1 (systemic RNAi defective 1), which is thought to be a passive channel for cell-to-cell RNA movement (Feinberg & Hunter 2003). In Arabidopsis, 21 nt siRNAs are transported from cell to cell for short distances (10–15 cells), and an unknown signal (probably dsRNA) is loaded into the phloem to provide long-distance transport of the silencing signal (Brosnan et al. 2007; Dunoyer et al. 2007; Dunoyer & Voinnet 2008). It has been argued that the short RNAs are likely to need to be amplified by an RdRp for the RNAi signal to be effectively propagated between cells, and in Arabidopsis movement beyond 15 cells is indeed dependent on RdRp function. However, many animals encode SID-1 homologues but not RdRps (see §6), and there is evidence of non-cell-autonomous RNAi in several taxa that lack their own RdRp (Jose & Hunter 2007).(b) The miRNA pathway The microRNA (miRNA; figure 1 (c) The piRNA and endogenous siRNA pathways A third group of RNAi-related pathways target transposable elements (TEs: transposons, retrotransposons and endogenous retroviruses; Aravin et al. 2007; Hartig et al. 2007; Matzke et al. 2007; Mevel-Ninio et al. 2007; Slotkin & Martienssen 2007; Chung et al. 2008; Czech et al. 2008; Ghildiyal et al. 2008; Kawamura et al. 2008). It was observed in as early as 1999 that several RNAi mutants of C. elegans had elevated rates of transposition (Ketting et al. 1999; Tabara et al. 1999), and it is now apparent that RNAi also plays an important role in determining the activity of TEs in many other eukaryotes (Vastenhouw & Plasterk 2004; Matzke et al. 2007; Zaratiegui et al. 2007; Czech et al. 2008). TE transcripts are processed by Argonaute and/or Dicer family members, both reducing transcript numbers and leading to epigenetic modification of genomic copies of the transposons, heterochromatin formation and reduced expression of TEs. In Arabidopsis, the pathway that targets transposons involves Dicer-like 3 and Argonaute 4, and a class of 24–26 nucleotide siRNAs derived from the TE transcripts (Matzke et al. 2007; Zaratiegui et al. 2007). In Drosophila and vertebrate germ lines, TE silencing relies on Argonaute proteins in the Piwi family, and a class of short RNAs known as Piwi-interacting short RNAs (piRNAs; Aravin et al. 2007; Hartig et al. 2007; Klattenhoff & Theurkauf 2008). These are longer (24–30 nt) than viRNAs and miRNAs, and originate from a single-stranded RNA (ssRNA) precursor without the involvement of a Dicer protein. In Drosophila, the majority of piRNAs target repeat sequences such as TEs (also known as repeat-associated siRNAs or rasiRNAs), while in vertebrates most target other repetitive sequences and only a minority are complementary to TEs. A model has been proposed in which the suppression of TEs is maintained by a cyclic feedback process that alternately cleaves sense and antisense TE transcripts (‘ping-pong’: figure 1Very recently, it has also been shown that Drosophila (Chung et al. 2008; Czech et al. 2008; Ghildiyal et al. 2008; Kawamura et al. 2008) and mice (Watanabe et al. 2008) have an additional RNAi pathway that targets endogenous dsRNA such as that produced by overlapping 3′-UTRs from genes on opposite strands, long hair-pin fold-back sequences and TEs (Chung et al. 2008; Czech et al. 2008; Ghildiyal et al. 2008; Kawamura et al. 2008; Okamura et al. 2008). In Drosophila, this pathway is similar to the antiviral pathway (figure 1 3. The viRNA pathway and host–virus coevolution Most organisms lack the adaptive immune system of vertebrates, and must rely on innate immunity to protect themselves from infection. The innate immune system often detects and destroys pathogens by recognizing families of molecules that are conserved across broad classes of pathogens (Medzhitov & Janeway 1997). In the case of bacteria and fungi, these molecules are primarily cell-surface polysaccharides, while viruses can be recognized if they produce dsRNA. dsRNA can be used to distinguish self from non-self because eukaryotes typically do not produce long stretches of dsRNA (other than that destined for processing by RNAi). However, many RNA viruses have double-stranded genomes, and even viruses with single-stranded genomes can produce dsRNA during replication, when viral RNA forms secondary structures, or when there are complementary sense and antisense replicative intermediates. DNA viruses can potentially also produce the dsRNA necessary for RNAi through secondary structure in their transcripts or sense–antisense transcript pairs (Ding & Voinnet 2007). It is now clear that the viRNA pathway (figure 1 (a) RNAi as innate antiviral immunity The possibility that RNAi might have an antiviral function was first raised in plants when experimentally induced ‘gene silencing’ was found to provide resistance to viruses carrying an identical sequence (Lindbo et al. 1993). It was then identified as a natural component of innate antiviral immunity when viruses were found to naturally induce a similar response (Covey et al. 1997; Ratcliff et al. 1997). For animals, antiviral RNAi was first identified in Drosophila cell culture, where the beetle Nodamura virus FHV (flock house virus) acts as both an initiator and a target of the viRNA pathway (Li et al. 2002). It was later confirmed as biologically relevant defence outside of cell culture using the natural host–virus combination of O'nyong-nyong virus (alphavirus; Togaviridae) and Anopheles gambiae mosquitoes (Keene et al. 2004). RNAi has subsequently been identified as a component of antiviral immunity in adult Drosophila (Galiana-Arnoux et al. 2006; van Rij et al. 2006; Wang et al. 2006; Zambon et al. 2006) and in nematode worms (Lu et al. 2005; Schott et al. 2005; Wilkins et al. 2005). Very recently, RNAi has also been identified as an important antiviral defence in fungi (Segers et al. 2007; Hammond et al. 2008). Therefore, although several isolated lineages lack components of RNAi (e.g. Saccharomyces), it is likely that the viRNA antiviral pathway is a shared character of most eukaryotes. It remains an open question as to whether this pathway might be a component of antiviral immunity in vertebrates (Cullen 2006; Ding & Voinnet 2007; Haasnoot et al. 2007). Although vertebrates encode relevant genes (including Argonaute, Dicer and SID family members; figure 5
(b) Viral suppression and evasion of the viRNA pathway Viral suppression of the immune system is a widespread phenomenon (e.g. Katze et al. 2002; Marques & Carthew 2007). It is therefore not surprising that many viruses inhibit the viRNA pathway by expressing viral suppressors of RNAi (VSRs; Li & Ding 2006; Ding & Voinnet 2007). Very soon after the natural antiviral role of RNAi was revealed, the Hc-Pro protein of plant Potyviruses (Anandalakshmi et al. 1998; Brigneti et al. 1998; Kasschau & Carrington 1998) and the 2b protein of plant cucumoviruses (Li et al. 1999) were identified as VSRs. The first VSR identified in an animal virus was the B2 protein of the beetle virus FHV, which was initially found to suppress RNAi in plants, before being shown to play the same role in insects (Li et al. 2002). As of 2006, Li and Ding were able to review the function of more than 50 VSRs from over 30 viral genera. This list includes all categories of RNA viruses (negative sense, positive sense and double stranded) and some DNA viruses, in both plants and animals. Although the VSR function of some of these genes has been questioned (especially those of negative-sense ssRNA animal viruses, e.g. Blakqori et al. 2007), it now appears that active suppression of the host viRNA pathways is often an important component of infection, and nearly universal in plant–RNA virus interactions (Li & Ding 2006; Ding & Voinnet 2007). VSRs appear so important for successful viral infection that several viruses encode multiple VSRs, e.g. Citrus Tristeza Virus (a Closterovirus) encodes three (Lu et al. 2004) and several potyviruses encode two (Valli et al. 2008). Many VSRs are dsRNA-binding proteins. However, while sequestering viRNA molecules away from the RNAi pathway is apparently the primary mechanism for some—such as P19 of tombusviruses, which shows a strong specificity for 21 nt dsRNA duplexes—it is now clear that there are a diverse range of other suppression mechanisms (Li & Ding 2006; Ding & Voinnet 2007). Indeed, not all VSRs are even proteins—at least two are thought to be RNAs, which may function by binding RNAi components in place of viRNAs. Different VSRs also target different components of RNAi (Ding & Voinnet 2007). For example, both Hc-Pro and B2 appear to inhibit viRNA processing from long dsRNA precursors by Dicer. Conversely, the 2b protein of cucumoviruses and the P0 protein of poleroviruses both target Argonaute family members; 2b by binding Arabidopsis Ago-1 directly to prevent the RISC complex from cleaving its target RNA (Zhang et al. 2006b), and P0 by targeting Argonaute family proteins for degradation (Baumberger et al. 2007).In plants, where cell-to-cell propagation of RNAi is a key feature of the viRNA pathway (and where assays for non-cell-autonomous silencing are best developed), VSRs differentially affect cell-autonomous RNAi, non-cell-autonomous RNAi and the vascular transport of RNAi (Ding & Voinnet 2007; Jose & Hunter 2007). For example, if the P38 VSR is deleted from Turnip Crinkle Virus (Tombusviridae), the virus is still able to move locally from cell to cell, but cannot spread through the entire plant (Deleris et al. 2006). Similarly, the Potexvirus VSR P25 does not effectively inhibit cell-autonomous RNAi, but does block long distance movement (Guo & Ding 2002). By contrast, Hc-Pro from potyviruses and AC2 from African cassava mosaic virus (a DNA geminivirus) are VSRs that suppress cell-autonomous and short-distance RNAi, respectively, but not long-distance export (Mallory et al. 2003; Vanitharani et al. 2004; Trinks et al. 2005). A second strategy may be for a virus to manipulate the host's own control of the pathway rather than suppressing RNAi directly. For example, the Begomovirus VSR (AC2) appears to act as a transcriptional regulator that alters the expression of approximately 50 host genes, including some that might modify RNAi activity (Trinks et al. 2005). Viruses may also reduce the effects of RNAi by preventing dsRNA from coming into contact with the RNAi pathway, or avoiding degradation once viRNAs have been produced. Viruses have several adaptations to reduce the production of dsRNA and shield the viral genome from degradation (Ahlquist 2002). For example, when single-stranded viruses replicate they must produce the complementary replication intermediate, and the nucleocapsid protein of negatively stranded viruses prevents the two strands from annealing and producing dsRNA. Because viRNAs are rarely derived uniformly from across the viral genome (e.g. Molnar et al. 2005; Deleris et al. 2006), it seems likely that certain regions of the genome are more vulnerable than others. The secondary structure of RNA can determine which fragments are processed to form viRNAs, and whether the active silencing complex has access to degrade the target RNA. For example, although viroids (subviral RNA pathogens that do not encode proteins) are a source of functional viRNAs, they are not cleaved by the silencing complex owing to their secondary structure (Itaya et al. 2007). When HIV is cultured with an artificial RNAi construct, its secondary structure evolves rapidly to block access by RNAi components, supporting the idea that this could be a viable mechanism of viral evasion, at least in principle (Westerhout et al. 2005). (c) Viral evolution in response to host RNAi There is clearly an evolutionary conflict between the viRNA pathway and its suppression by viruses. This has the potential to result in a never-ending arms race, where the RNAi pathway continually evolves new ways to escape suppression by VSRs, which leads to counteradaptations by the virus that restore suppression (Carthew 2006; Obbard et al. 2006). If this is the case, then VSRs might be expected to evolve much faster than other viral genes. This is certainly true when comparing VSRs across different viral families (Li & Ding 2006; Ding & Voinnet 2007). Li & Ding (2006) observed that VSRs from different viral families have essentially no structural similarity, even where they have similar functions. This is particularly striking when the dsRNA-binding motifs are compared across different VSRs: the dsRNA-binding domains from P19 (tombusviruses), P21 (Beet Yellows Virus) and B2 (FHV) each appear to have evolved different and entirely novel dsRNA-binding motifs (reviewed by Li & Ding 2006). Many VSRs also appear to have arisen relatively recently, and it has been argued that this is an indication of frequent viral adaptation to host RNAi (Li & Ding 2006). If VSRs are engaged in an evolutionary arms race, then we might also expect to see the rapid sequence evolution of homologous VSRs within the same virus family. There is circumstantial evidence that this is the case (Li & Ding 2006). For example, the P1 VSR of potyviruses (Valli et al. 2006, 2008) is highly variable both in length and sequence, and shows evidence of recombination between potyviral lineages (Valli et al. 2007). Potyviruses typically have a second VSR called Hc-Pro, but in cucumber vein yellowing virus from the related genus Ipomovirus, Hc-Pro has been lost and its function appears to have been taken on by a tandemly duplicated copy of P1 (Valli et al. 2006). Similarly, in the Closteroviridae there is a considerable sequence diversity in the VSR P22 (Cuellar et al. 2008), and in one species (Sweet Potato Chlorotic Stunt Virus) some viral isolates have lost this suppressor altogether but still maintain VSR activity, presumably from a second locus (Cuellar et al. 2008). To test whether VSRs evolve faster than other viral genes, we analysed the rate of protein divergence for all genes in pairs of isolates from 17 ssRNA plant viruses with experimentally verified VSRs (figure 2
(d) Subversion of the viRNA pathway There is evidence that some viruses might have evolved to subvert the viRNA pathway for their own benefit (reviewed by Ding & Voinnet 2007). Several short RNAs derived from Cauliflower Mosaic Virus are complementary to Arabidopsis messenger RNAs, and downregulate those genes (Moissiard & Voinnet 2006). This may be coincidental rather than adaptive—since Arabidopsis is unlikely to be a natural host for cauliflower mosaic virus, this would require the short RNA targets to be very highly conserved between members of the Brassicaceae—but again illustrates the potential for viral evolution in response to host RNAi. It opens up interesting opportunities for the virus, as these host-manipulating viRNAs could in principle be exported from the site of infection and ‘prime’ the rest of the plant for viral invasion (Ding & Voinnet 2007). (e) The evolution of host viRNA-pathway genes Because many viruses rely on suppressing the viRNAi pathway to infect their hosts, there will be a considerable advantage to mutations in viRNAi genes that escape this suppression. Furthermore, as the VSRs themselves are evolving quickly, the viRNAi pathway faces a continually changing array of suppressors to adapt to, and this could result in an evolutionary arms race driving the rapid evolution of both host and viral proteins. As predicted by this hypothesis, three key proteins in the viRNAi pathway of Drosophila (Dcr-2, Ago-2 and R2D2) are among the top 3 per cent of the most rapidly evolving in the entire genome (Obbard et al. 2006; figure 3
However, rapid protein evolution need not be caused by positive natural selection, but can also result from low selective constraints. If a gene is evolving neutrally, the ratio of non-synonymous (amino acid changing) to synonymous differences between species will be the same as the ratio for polymorphism within species (McDonald & Kreitman 1991). In the case of the viRNAi genes, the high amino acid divergence between species is not matched by the high levels of amino acid polymorphism, providing compelling evidence that selection has driven the rapid evolution of these genes (Obbard et al. 2006). Using this excess of amino acid divergence relative to polymorphism, we have estimated the number of amino acid differences between Drosophila melanogaster and its close relative Drosophila simulans that were fixed because they had a selective advantage (figure 4
4. The miRNA pathway and host–virus coevolution It has recently become clear that the miRNA pathway can also play a role in host–virus interactions (Sarnow et al. 2006). Unlike the viRNA pathway, which primarily uses short RNAs derived from viruses as an immune defence, both host and virus sequences can be processed into miRNAs, and the miRNA pathway is not only antiviral but can also be exploited by viruses for their own benefit. (a) Virus-encoded miRNAs Virus-encoded miRNAs were first identified in the Epstein–Barr virus (EBV; Pfeffer et al. 2004) and have now been found in at least 12 mammalian viruses, spanning the three herpesvirus subfamilies, polyomaviruses and retroviruses (for a current listing see the miRBase Sequence Database; Griffiths-Jones et al. 2008) (for a review see Sarnow et al. 2006). The miRNA pathway (figure 1 It has been estimated that more than 50 per cent of the genes in herpesviruses and poxviruses could be devoted to manipulating the host immune system (Alcami & Koszinowski 2000) and viral miRNAs are an efficient way to do this as they only require a small amount of coding sequence in the genome, yet can have a large capacity for gene regulation as they can have multiple targets. This field is in its infancy and the actual number of targets and in vivo functions of virus-encoded miRNAs remains to be elucidated. However, a recent report demonstrates that a miRNA encoded by Human Cytomegalovirus (HCMV) can target the MHC class I-related chain B gene (Stern-Ginossar et al. 2007) and thereby protect HCMV-infected cells from lysis by natural killer cells. Kaposi's sarcoma-associated herpesvirus appears to use a different strategy to manipulate host function: it encodes a miRNA (termed mir-k12-11) that mimics the host-encoded miRNA mir-155, both having the same sequence in the seed region and sharing several targets (Gottwein et al. 2007; Skalsky et al. 2007). Some of these genes regulate cell growth and B-cell transformation, so the miRNA may be partly responsible for B-cell tumours in infected patients. Given the apparent benefits to the virus, it might be expected that many viral lineages will be found to encode miRNAs. Of the 12 viruses reported to encode miRNAs, 10 belong to the herpesvirus family, one belongs to the polyomavirus family and one to the retrovirus family. This bias is at least partly attributable to the large volume of research aimed at herpesviral miRNAs (Grey et al. 2008) and additional sequencing efforts will be required to understand the generality of viral-miRNA existence. However, computational analyses reveal a low probability that pre-miRNA structures occur in human and mouse ssDNA and ssRNA viruses, and cloning efforts failed to identify miRNAs in RNA viruses including Yellow Fever Virus and Hepatitis C Virus (Pfeffer et al. 2005). Indeed, with the exception of miRNAs recently reported from HIV, viral miRNAs have only been found in dsDNA viruses. Why might this be? First, the primary miRNA-processing machinery (e.g. Drosha) is found in the nucleus, and thus is unlikely to be available to cytoplasmic viruses. Second, host-targeted viral miRNAs must match the host sequences, and may only have time to evolve where there is a long-term host–parasite association. Third, some viruses produce VSRs that can inhibit the miRNA pathway. These factors may explain the apparent bias for miRNA representation in herpesviruses, which replicate in the nucleus, tend to remain associated with the same host lineage for millions of years (Sharp 2002), and are not known to inhibit the miRNA pathway. (b) Host-encoded miRNAs Hosts can also use the miRNAs pathway as a defence against viruses by expressing miRNAs that target viral RNA (Lecellier et al. 2005; Pedersen et al. 2007). For example, Primate Foamy Virus 1 (PFV-1) mRNA is targeted by the human miRNA mir-32, which results in decreased PFV-1 replication (Lecellier et al. 2005). However, the physiological relevance of this might be questioned, since mir-32 may not be expressed in cell types relevant to PFV-1 replication (Cullen 2006), foamy viruses currently only occur as rare zoonoses in humans (Calattini et al. 2007) and it is not known whether the target sequence is conserved in related viruses that regularly infect humans. In another recent report, mice deficient in Dicer-1 were shown to be more susceptible to infection by Vesicular Stomatitis Virus (VSV) (Otsuka et al. 2007): two cellular miRNAs, mir-24 and mir-93, are predicted to target VSV genes encoding the viral RdRp and a polymerase cofactor, and mutation of the miRNA-binding sites in these genes rescues the growth defect in Dicer-1 deficient cells (Otsuka et al. 2007). It has also been suggested that miRNAs may be an effector in the classical vertebrate innate immune response (Pedersen et al. 2007). Activation of the interferon beta pathway in human cells infected by Hepatitis C Virus induces the expression of several host-encoded miRNAs, some of which have predicted targets in the virus (Pedersen et al. 2007). In support of their antiviral role, when these miRNAs are experimentally introduced they reproduce the antiviral effects of interferon beta on HCV, and the interferon defence is lost when they are experimentally removed (Pedersen et al. 2007). It appears that host miRNAs can also modulate cellular genes involved in the interferon response, as demonstrated for mir-146 (Taganov et al. 2006), and the expression of mir-146 is induced by the EBV-encoded latent membrane protein (LMP1) (Cameron et al. 2008), which suggests an intricate role of miRNAs in viral–host interactions. Viruses may also exploit host-encoded miRNAs for their own advantage. For example, Hepatitis C Virus requires a host miRNA expressed in the liver, mir-122, which interacts with the 5′-non-coding region of the viral genome to increase replication (Jopling et al. 2005). Moreover, the host innate immune response downregulates mir-122, presumably reducing the viral replication (Pedersen et al. 2007). (c) Host–virus coevolution in the miRNA pathway In the viRNA pathway, short RNAs are derived from the virus itself and will thus always match the target. This means that there is no possibility of the viral genome evolving to avoid sequence-based recognition. This is clearly important, as when a ‘fixed’ siRNA sequence is experimentally applied (i.e. one that is exogenous, rather than derived from the virus), the targeted viral sequence rapidly evolves to avoid being targeted (Westerhout et al. 2005). By contrast, in the miRNA pathway both host- and virus-encoded miRNAs may have an opportunity to coevolve with the target sequences in their opponent. As viruses generally evolve faster, thanks to their larger population sizes, shorter generation times and higher mutation rates, they may often have the upper hand. Host-encoded miRNAs involved in the control of gene expression are often conserved over long periods of evolutionary time in both plants (Zhang et al. 2006a; Willmann & Poethig 2007) and animals (Bartel 2004; Ruby et al. 2007). Superficially, this might suggest that miRNA sequences are not engaged in rapid arms race evolution. However, recent sequencing of Drosophila miRNAs, in conjunction with analysis of 12 Drosophila genomes, suggests that some miRNAs are evolutionarily young and can be frequently gained and lost (Lu et al. 2008), opening up the possibility that there may be a class of rapidly evolving miRNAs that could target and coevolve with viruses. The VSRs of plant viruses typically suppress the miRNA pathway as well as the viRNA pathways, and viral suppression of the host miRNA functions can be a major cost of infection (Kasschau et al. 2003; Chapman et al. 2004). Similarly, many viruses of vertebrates encode genes that suppress both RNAi pathways, possibly as a by-product of suppressing the interferon response (Cullen 2006). Given the possibility of antiviral miRNAs, it now seems plausible that this is an adaptive strategy. However, because many viruses use the miRNA pathway for their own advantage, a trade-off may occur between a virus' ability to suppress RNAi, and its ability to use miRNAs to its own advantage. Such a trade-off might not occur in Drosophila, where there is a separation of the core miRNA and viRNA pathways (Kavi et al. 2005), and VSRs do not impede the miRNA pathway in vivo (Chou et al. 2007). 5. Heterochromatin, the piRNA pathway, and intragenomic conflict (a) RNAi as a defence against TEs TEs copy themselves throughout the genome, and can harm the host when they cause mutations or ectopic recombination (reviewed by Charlesworth et al. 1994). RNAi can act as a defence against TEs, both by degrading transcripts, and by preventing expression by heterochromatin formation (Grewal & Elgin 2007; Matzke et al. 2007; Slotkin & Martienssen 2007; Zaratiegui et al. 2007). Heterochromatin is usually strongly enriched for TEs (Zaratiegui et al. 2007), and although it is required for cellular functions such as the control of gene expression and successful chromosome segregation, it has been widely suggested that it originally evolved as an anti-TE defence (Grewal & Elgin 2007; Slotkin & Martienssen 2007; Zaratiegui et al. 2007). The de novo initiation of heterochromatic silencing, including that targeted against TEs, seems almost universally mediated by RNAi-related pathways (Grewal & Elgin 2007; Zaratiegui et al. 2007), and in many organisms RNAi also plays a central role in its ongoing maintenance (Grewal & Elgin 2007). In Arabidopsis, more than half the endogenous siRNAs are derived from heterochromatic sequence, and a third of these target TEs and other repeats (Matzke et al. 2007). Here, the 24–26 nt siRNAs that target TEs are produced by a Dicer family member (DCL3), and then bound by an Ago-4-containing complex that targets the genomic copies of the TE for methylation and heterochromatin formation. A host RdRp (RDR2) is also required, suggesting that there may be an amplification step. Although it is not yet certain how this anti-TE RNAi is initiated, it has been suggested that dsRNA may be generated both by antisense TE transcripts expressed by host promoters, and by fold-back structures such as those resulting from inverted terminal repeats produced by some classes of TE (Slotkin & Martienssen 2007).In vertebrates and Drosophila the piRNA pathway (figure 1 In C. elegans, several RNAi-pathway genes are necessary for silencing DNA transposons in the germ line (Tabara et al. 1999; Sijen & Plasterk 2003), and numerous siRNAs are derived from TE sequences (Ruby et al. 2006). However, although Piwi family Argonautes are found in C. elegans and are required for germ line function, with the exception of the TE Tc3 (Das et al. 2008), the C. elegans Piwi-related genes (PRG-1 and PRG-2) do not appear to be required for the suppression of TE transposition (Batista et al. 2008). Very recently, a second anti-TE RNAi pathway has been identified in Drosophila (Chung et al. 2008; Czech et al. 2008; Ghildiyal et al. 2008; Kawamura et al. 2008). This pathway uses Ago-2 and Dicer-2 from the viRNA pathway, and processes the TE transcripts into endogenous siRNAs in both somatic (Chung et al. 2008) and germ line (Czech et al. 2008) tissue. Although it has not yet been shown to affect rates of transposition, both Ago-2 and Dcr-2 knockouts display increased levels of TE transcript, strongly suggesting that this may be a second regulatory mechanism. Why two different RNAi pathways should be required to suppress TEs is unclear: it is possible that there is crosstalk between the pathways, and it has been hypothesized that the second pathway may be involved in the maintenance of heterochromatin in somatic tissue (Kawamura et al. 2008; Obbard & Finnegan 2008). (b) Evolution of the piRNA pathway in Drosophila In the germ line, the conflict between the host genome and TEs could drive an evolutionary arms race (Charlesworth & Langley 1989), in the same way as has been hypothesized for viruses (Obbard et al. 2006; Marques & Carthew 2007). In support of this, a recent analysis of the genome sequences of 12 species of Drosophila found that natural selection has driven the rapid evolution of both Krimper and Spindle-E (Heger & Ponting 2007). To examine the other piRNA-pathway genes, we have summarized the rate of protein evolution in several components of the piRNA pathway (figure 3 6. The phylogenetic distribution of RNAi components While the core machinery of the RNAi pathways (figure 1 The distribution of RdRps, which are thought to be required for signal amplification, is a striking example. With extensive genome data now available from all major metazoan groups, we have been able to identify this gene in lineages on each major branch of the bilateria, consistent with its presence in the metazoan ancestor (figure 5 SID-1, which was first identified in nematodes and forms a channel for cell-to-cell movement of dsRNA, has no orthologue in plants, but it does in many animal lineages—with the notable exception of the dipterans (figure 5 Dicer genes also show considerable variation among eukaryotic lineages. In plants, for example, there are larger numbers—Arabidopsis has four Dicer-like genes—and these show some functional redundancy (reviewed by Ding & Voinnet 2007). For example, resistance phenotypes against some viral infections are seen in Arabidopsis only when multiple Dicers are knocked out, suggesting that they can substitute for each other (Deleris et al. 2006). In Arabidopsis, it appears that the Dicer DCL4 is a primary effector against ssRNA viruses, but that DCL2 substitutes when DCL4 is knocked out or suppressed, and DCL3 (which normally mediates chromatin modification) plays an important role in some viral infections, and in DCL2/DCL4 double mutants (Moissiard & Voinnet 2006; Ding & Voinnet 2007). This may suggest that, in plants at least, multiple paralogous viRNA-pathway genes have specialized functions, perhaps evolving in response to viral suppression of RNAi. In animals, one or two Dicers have been found in all genomes explored to date, with the exception of Daphnia (figure 5 Even more striking is the variability in the components of the RISC complexes. Although it is not always clear that they function within RNAi-related pathways, Argonaute family members, in particular, seem to be very variable in number (Hock & Meister 2008; Hutvagner & Simard 2008; Murphy et al. 2008)—Arabidopsis has 10, fission yeast (Schizosaccharomyces pombe) 1, Drosophila 5, and C. elegans in excess of 20. Why this should be is not clear. Although there is sometimes pathway specialization (Piwi-like Argonautes function in the piRNA pathway), there is also overlap between the pathways, and genes can be functionally redundant. In the nematode, there is discrimination in loading siRNAs or miRNAs onto RISCs after processing by its single Dicer (Jannot et al. 2008), so that short RNAs with different functional roles are associated with different members of the large family of Argonautes. The siRNAs are found bound to RDE-1, which has RNase H activity (Yigit et al. 2006); by contrast, miRNAs are bound to the Argonaute proteins ALG-1 and ALG-2 (Gu et al. 2007). Insects and vertebrates appear to show less discrimination in this respect. In Drosophila, miRNAs and siRNAs are generated by distinct Dicers but the duplex intermediates undergo independent sorting processes, one involving Dcr-2/R2D2 that favours loading of siRNAs into Ago-2 (Tomari et al. 2007), and may be loaded into Ago-1 or into Ago-2 (Okamura et al. 2004; Forstemann et al. 2007). Ago-1 has inefficient RNase H activity (Valencia-Sanchez et al. 2006), so that only Ago-2 is capable of cleaving target RNAs, where there is sufficient complementarity (Zeng et al. 2003). In humans, which also have only one Dicer, miRNAs may be loaded onto any of the four proteins Ago-1–4; only Ago-2 has RNase H activity (Meister & Tuschl 2004). 7. Outlook and prospects Despite evolution and arms races being frequently mentioned in the RNAi literature, there are still few explicitly evolutionary studies of RNAi. In this final section, we highlight three interesting topics for future work. (a) Specific immune responses In this review, we have discussed how coevolution between hosts and parasites can take the form of an arms race, in which novel mutations that either increase resistance or overcome this resistance sweep through the host and parasite populations. However, coevolution can also act to maintain genetic variation in the resistance of individuals in host populations and infectivity of strains in populations (Woolhouse et al. 2002). This occurs because as the frequency of a resistance allele increases in the host population, the frequency of the pathogens it targets and hence its selective advantage can decrease. If the resistant allele confers susceptibility to other pathogen genotypes, or has some other fitness cost, there comes a point where it is at a selective disadvantage. An analogous process can occur within the parasite population. This results in negative frequency-dependent selection, and can maintain genetic variation in populations and promote complex dynamics, such as cycles in allele frequency. It is possible that this form of coevolution could maintain variation in RNAi genes and viral populations. For example, because host-encoded miRNAs that target viral sequences are a form of specific immunity that is germ line encoded (as opposed to viRNAs, where immunity is acquired after infection), antiviral miRNAs will select for escape mutants in the viral population, and these escape mutants could in turn select for matching miRNAs. This could lead to specific ‘matching alleles’ in the host and viral population, in which each host allele confers resistance to some viral genotypes but susceptibility to others, resulting in the coevolutionary dynamics described above (Hamilton 1980) This could both maintain genetic variation in miRNAs and their viral targets, and lead to dynamic changes in the effectiveness of miRNA defences through time and space. (b) Acquired immunity Unlike the miRNA pathway, where immunity is germ line encoded and may take many generations to evolve, highly specific viRNA-based immunity can develop rapidly after exposure to the virus. In this respect, the viRNAi pathway is reminiscent of the acquired immune response of vertebrates, which is also highly specific and develops after infection. In vertebrates, acquired immunity can maintain a high diversity of antigens in the parasite population—hosts are most likely to be immune to common antigenic types, so there is an advantage to rare antigen alleles (Hughes 1991). A similar process can occur within an infected host, where mutations in antigens that escape the immune response may be favoured, leading to a turnover of antigens through time (Allen et al. 2000). Could such processes occur in response to the viRNAi pathway? Plants that have been infected by a virus can develop new growth that is free from viral infection and resistant to secondary infection due to RNAi targeted against the virus (Baulcombe 2004). If these hosts are exposed to a second viral strain, then this incoming strain may have an advantage if it is not recognized by viRNAs derived from the resident strain. This could potentially maintain genetic polymorphisms in the viral population. Similarly, there may be selection for mutants that escape recognition by the viRNA pathway within an infected host, by evolving new (and thus rare) sequences (Ding & Voinnet 2007). However, the acquired immune response of vertebrates and viRNA differ in the speed of the response, whether or not it is systemic, and the number of different epitopes or viRNAs produced from a pathogen, and these factors may all affect the outcome. These ideas could be tested both theoretically and experimentally. (c) Why do RNAi-related genes evolve so fast? In Drosophila, antiviral and anti-TE RNAi genes are among the most rapidly evolving genes in the genome (figures 4 An alternative explanation for rapid evolution in the Drosophila piRNA pathway might be that some piRNA components also have antiviral function in addition to their anti-TE role. In support of this, some piRNA-pathway mutants appear to be more susceptible to a dsRNA virus (although these results await further experimental confirmation; Zambon et al. 2006), and there is an extensive overlap between the antiviral and anti-TE pathways in other organisms (e.g. Moissiard & Voinnet 2006; Brosnan et al. 2007). Moreover, components of the piRNA pathway might also interact with DNA viruses and retroviruses. First, DNA virus function often depends upon chromatin status (e.g. Jenkins et al. 2000) and in plants this can be mediated by RNAi (Bian et al. 2006). Second, the distinction between retroviruses and retrotransposons is a subtle one (retrotransposons are often considered ‘endogenous retroviruses’; e.g. Kim et al. 1994; Lecher et al. 1997) and in Drosophila retrotransposons are silenced by the piRNA pathway in the germ line (Mevel-Ninio et al. 2007; Pelisson et al. 2007), opening up the possibility that the piRNA pathway could also suppress ‘true’ retroviruses. It is also possible that a factor other than viruses or TEs drives rapid adaptive evolution in both RNAi pathways. For example, both Ago-2 and Dcr-2 have other germ line functions in Drosophila (Deshpande et al. 2005; Jin & Xie 2007), and the Piwi family genes of both C. elegans (Batista et al. 2008) and Drosophila have non-TE-related germ line functions, such as mediating the silencing of other potentially ‘selfish’ sequences such as Stellate in Drosophila (Vagin et al. 2006; Aravin et al. 2007). Indeed, in general, the most rapidly evolving genes in Drosophila are those that regulate chromatin, mediate nuclear import and export, and are involved in meiosis and reproduction (Begun et al. 2007), and it may be that rapidly evolving RNAi genes are a part of this phenomenon. Thus, although viruses remain a prime candidate, it remains an open question as to whether viruses, TEs, other parasites, meiotic drive, sexual conflict or something else entirely has driven the adaptive evolution seen in RNAi-pathway genes. Acknowledgements We thank Andreas Heger for alignments used in figure 3 Footnotes One contribution of 11 to a Theme Issue ‘Ecological immunology’. Supplementary text 1: accession data for figure 2 Genbank accession numbers for the sequences used in figure 2 Click here to view.(20K, doc) Supplementary figure 1: alignment RdRp of metazoan RdRps Alignment of sequences of RdRps from selected animal and other genomes Click here to view.(47K, doc) Supplementary table 1: numbers used for the MK tests shown in figure 4 of the main test Numbers used for the MK tests shown in figure 4 of the main test Click here to view.(70K, doc) References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Curr Biol. 2007 Sep 18; 17(18):R789-93.
[Curr Biol. 2007]RNA. 2007 Jul; 13(7):1090-102.
[RNA. 2007]Nat Rev Immunol. 2008 Feb; 8(2):120-30.
[Nat Rev Immunol. 2008]Curr Genet. 2006 Aug; 50(2):81-99.
[Curr Genet. 2006]Philos Trans R Soc Lond B Biol Sci. 2006 Jun 29; 361(1470):1039-54.
[Philos Trans R Soc Lond B Biol Sci. 2006]Genetics. 2003 Aug; 164(4):1471-80.
[Genetics. 2003]Proc R Soc Lond B Biol Sci. 1979 Sep 21; 205(1161):489-511.
[Proc R Soc Lond B Biol Sci. 1979]Curr Biol. 2006 Mar 21; 16(6):580-5.
[Curr Biol. 2006]Science. 2007 Nov 2; 318(5851):761-4.
[Science. 2007]Trends Genet. 2007 Jul; 23(7):359-64.
[Trends Genet. 2007]Science. 2007 Nov 2; 318(5851):761-4.
[Science. 2007]Nat Rev Genet. 2007 Nov; 8(11):884-96.
[Nat Rev Genet. 2007]Cell. 2007 Aug 10; 130(3):413-26.
[Cell. 2007]Genes Dev. 2007 Jul 15; 21(14):1707-13.
[Genes Dev. 2007]Curr Biol. 2007 Sep 18; 17(18):R789-93.
[Curr Biol. 2007]Cell. 2007 Aug 10; 130(3):413-26.
[Cell. 2007]Nat Chem Biol. 2007 Jan; 3(1):36-43.
[Nat Chem Biol. 2007]Nat Rev Genet. 2007 Nov; 8(11):884-96.
[Nat Rev Genet. 2007]Annu Rev Genet. 2007; 41():305-30.
[Annu Rev Genet. 2007]Science. 2007 Jan 12; 315(5809):241-4.
[Science. 2007]Science. 2007 Jan 12; 315(5809):244-7.
[Science. 2007]EMBO J. 2003 Sep 1; 22(17):4523-33.
[EMBO J. 2003]Annu Rev Genet. 2007; 41():305-30.
[Annu Rev Genet. 2007]Science. 2003 Sep 12; 301(5639):1545-7.
[Science. 2003]Nat Genet. 2007 Jul; 39(7):848-56.
[Nat Genet. 2007]Trends Genet. 2008 Apr; 24(4):151-4.
[Trends Genet. 2008]Curr Opin Genet Dev. 2006 Apr; 16(2):203-8.
[Curr Opin Genet Dev. 2006]Annu Rev Cell Dev Biol. 2007; 23():175-205.
[Annu Rev Cell Dev Biol. 2007]Nat Rev Genet. 2007 Nov; 8(11):884-96.
[Nat Rev Genet. 2007]Trends Cell Biol. 2007 Mar; 17(3):118-26.
[Trends Cell Biol. 2007]Development. 2005 Nov; 132(21):4645-52.
[Development. 2005]Science. 2007 Nov 2; 318(5851):761-4.
[Science. 2007]Genes Dev. 2007 Jul 15; 21(14):1707-13.
[Genes Dev. 2007]Curr Opin Plant Biol. 2007 Oct; 10(5):512-9.
[Curr Opin Plant Biol. 2007]Genetics. 2007 Apr; 175(4):1615-24.
[Genetics. 2007]Nat Rev Genet. 2007 Apr; 8(4):272-85.
[Nat Rev Genet. 2007]Curr Opin Plant Biol. 2007 Oct; 10(5):512-9.
[Curr Opin Plant Biol. 2007]Cell. 2007 Feb 23; 128(4):763-76.
[Cell. 2007]Science. 2007 Nov 2; 318(5851):761-4.
[Science. 2007]Genes Dev. 2007 Jul 15; 21(14):1707-13.
[Genes Dev. 2007]Development. 2008 Jan; 135(1):3-9.
[Development. 2008]Curr Biol. 2008 Jun 3; 18(11):795-802.
[Curr Biol. 2008]Nature. 2008 Jun 5; 453(7196):729-31.
[Nature. 2008]Science. 2008 May 23; 320(5879):1077-81.
[Science. 2008]Nature. 2008 May 22; 453(7194):539-43.
[Nature. 2008]Nature. 2008 Jun 5; 453(7196):803-6.
[Nature. 2008]Cell. 1997 Oct 31; 91(3):295-8.
[Cell. 1997]Cell. 2007 Aug 10; 130(3):413-26.
[Cell. 2007]Plant Cell. 1993 Dec; 5(12):1749-1759.
[Plant Cell. 1993]Science. 1997 Jun 6; 276(5318):1558-60.
[Science. 1997]Science. 2002 May 17; 296(5571):1319-21.
[Science. 2002]Nat Immunol. 2006 Jun; 7(6):590-7.
[Nat Immunol. 2006]Genes Dev. 2006 Nov 1; 20(21):2985-95.
[Genes Dev. 2006]Nat Immunol. 2006 Jun; 7(6):563-7.
[Nat Immunol. 2006]Cell. 2007 Aug 10; 130(3):413-26.
[Cell. 2007]Nat Biotechnol. 2007 Dec; 25(12):1435-43.
[Nat Biotechnol. 2007]Nat Rev Immunol. 2002 Sep; 2(9):675-87.
[Nat Rev Immunol. 2002]Trends Genet. 2007 Jul; 23(7):359-64.
[Trends Genet. 2007]Annu Rev Microbiol. 2006; 60():503-31.
[Annu Rev Microbiol. 2006]Cell. 2007 Aug 10; 130(3):413-26.
[Cell. 2007]Proc Natl Acad Sci U S A. 1998 Jan 6; 95(1):13-7.
[Proc Natl Acad Sci U S A. 1998]Annu Rev Microbiol. 2006; 60():503-31.
[Annu Rev Microbiol. 2006]Cell. 2007 Aug 10; 130(3):413-26.
[Cell. 2007]Genes Dev. 2006 Dec 1; 20(23):3255-68.
[Genes Dev. 2006]Curr Biol. 2007 Sep 18; 17(18):1609-14.
[Curr Biol. 2007]Cell. 2007 Aug 10; 130(3):413-26.
[Cell. 2007]Annu Rev Genet. 2007; 41():305-30.
[Annu Rev Genet. 2007]Science. 2006 Jul 7; 313(5783):68-71.
[Science. 2006]EMBO J. 2002 Feb 1; 21(3):398-407.
[EMBO J. 2002]Plant J. 2003 Jul; 35(1):82-92.
[Plant J. 2003]Science. 2002 May 17; 296(5571):1270-3.
[Science. 2002]J Virol. 2005 Jun; 79(12):7812-8.
[J Virol. 2005]Science. 2006 Jul 7; 313(5783):68-71.
[Science. 2006]J Virol. 2007 Mar; 81(6):2980-94.
[J Virol. 2007]Nucleic Acids Res. 2005; 33(2):796-804.
[Nucleic Acids Res. 2005]Curr Opin Genet Dev. 2006 Apr; 16(2):203-8.
[Curr Opin Genet Dev. 2006]Curr Biol. 2006 Mar 21; 16(6):580-5.
[Curr Biol. 2006]Annu Rev Microbiol. 2006; 60():503-31.
[Annu Rev Microbiol. 2006]Cell. 2007 Aug 10; 130(3):413-26.
[Cell. 2007]Annu Rev Microbiol. 2006; 60():503-31.
[Annu Rev Microbiol. 2006]J Virol. 2008 Jan; 82(2):974-86.
[J Virol. 2008]J Gen Virol. 2007 Mar; 88(Pt 3):1016-28.
[J Gen Virol. 2007]J Gen Virol. 2008 Feb; 89(Pt 2):573-82.
[J Gen Virol. 2008]Cell. 2007 Aug 10; 130(3):413-26.
[Cell. 2007]Curr Biol. 2006 Mar 21; 16(6):580-5.
[Curr Biol. 2006]Curr Biol. 1999 Jul 15; 9(14):747-50.
[Curr Biol. 1999]Genetics. 2003 Aug; 164(4):1471-80.
[Genetics. 2003]Nature. 1991 Jun 20; 351(6328):652-4.
[Nature. 1991]Curr Biol. 2006 Mar 21; 16(6):580-5.
[Curr Biol. 2006]Genome Res. 2007 Dec; 17(12):1837-49.
[Genome Res. 2007]Nat Rev Microbiol. 2006 Sep; 4(9):651-9.
[Nat Rev Microbiol. 2006]Science. 2004 Apr 30; 304(5671):734-6.
[Science. 2004]Nucleic Acids Res. 2008 Jan; 36(Database issue):D154-8.
[Nucleic Acids Res. 2008]Nat Rev Microbiol. 2006 Sep; 4(9):651-9.
[Nat Rev Microbiol. 2006]Nature. 2005 Jun 2; 435(7042):682-6.
[Nature. 2005]Trends Microbiol. 2000 Sep; 8(9):410-8.
[Trends Microbiol. 2000]Science. 2007 Jul 20; 317(5836):376-81.
[Science. 2007]Nature. 2007 Dec 13; 450(7172):1096-9.
[Nature. 2007]Med Microbiol Immunol. 2008 Jun; 197(2):261-7.
[Med Microbiol Immunol. 2008]Nat Methods. 2005 Apr; 2(4):269-76.
[Nat Methods. 2005]Cell. 2002 Feb 8; 108(3):305-12.
[Cell. 2002]Science. 2005 Apr 22; 308(5721):557-60.
[Science. 2005]Nature. 2007 Oct 18; 449(7164):919-22.
[Nature. 2007]Nat Immunol. 2006 Jun; 7(6):563-7.
[Nat Immunol. 2006]Emerg Infect Dis. 2007 Sep; 13(9):1314-20.
[Emerg Infect Dis. 2007]Immunity. 2007 Jul; 27(1):123-34.
[Immunity. 2007]Science. 2005 Sep 2; 309(5740):1577-81.
[Science. 2005]Nature. 2007 Oct 18; 449(7164):919-22.
[Nature. 2007]Nucleic Acids Res. 2005; 33(2):796-804.
[Nucleic Acids Res. 2005]Plant J. 2006 Apr; 46(2):243-59.
[Plant J. 2006]Curr Opin Plant Biol. 2007 Oct; 10(5):503-11.
[Curr Opin Plant Biol. 2007]Cell. 2004 Jan 23; 116(2):281-97.
[Cell. 2004]Genome Res. 2007 Dec; 17(12):1850-64.
[Genome Res. 2007]Nat Genet. 2008 Mar; 40(3):351-5.
[Nat Genet. 2008]Dev Cell. 2003 Feb; 4(2):205-17.
[Dev Cell. 2003]Genes Dev. 2004 May 15; 18(10):1179-86.
[Genes Dev. 2004]Nat Immunol. 2006 Jun; 7(6):563-7.
[Nat Immunol. 2006]FEBS Lett. 2005 Oct 31; 579(26):5940-9.
[FEBS Lett. 2005]Fly (Austin). 2007 Nov-Dec; 1(6):311-6.
[Fly (Austin). 2007]Nature. 1994 Sep 15; 371(6494):215-20.
[Nature. 1994]Nature. 2007 May 24; 447(7143):399-406.
[Nature. 2007]Curr Opin Plant Biol. 2007 Oct; 10(5):512-9.
[Curr Opin Plant Biol. 2007]Nat Rev Genet. 2007 Apr; 8(4):272-85.
[Nat Rev Genet. 2007]Cell. 2007 Feb 23; 128(4):763-76.
[Cell. 2007]Nature. 2007 May 24; 447(7143):399-406.
[Nature. 2007]Cell. 2007 Feb 23; 128(4):763-76.
[Cell. 2007]Curr Opin Plant Biol. 2007 Oct; 10(5):512-9.
[Curr Opin Plant Biol. 2007]Nat Rev Genet. 2007 Apr; 8(4):272-85.
[Nat Rev Genet. 2007]Science. 2007 Nov 2; 318(5851):761-4.
[Science. 2007]Genes Dev. 2007 Jul 15; 21(14):1707-13.
[Genes Dev. 2007]Dev Cell. 2007 Apr; 12(4):503-14.
[Dev Cell. 2007]Development. 2008 Jan; 135(1):3-9.
[Development. 2008]Dev Cell. 2007 Jun; 12(6):851-62.
[Dev Cell. 2007]Cell. 1999 Oct 15; 99(2):123-32.
[Cell. 1999]Nature. 2003 Nov 20; 426(6964):310-4.
[Nature. 2003]Cell. 2006 Dec 15; 127(6):1193-207.
[Cell. 2006]Mol Cell. 2008 Jul 11; 31(1):79-90.
[Mol Cell. 2008]Mol Cell. 2008 Jul 11; 31(1):67-78.
[Mol Cell. 2008]Curr Biol. 2008 Jun 3; 18(11):795-802.
[Curr Biol. 2008]Nature. 2008 Jun 5; 453(7196):729-31.
[Nature. 2008]Science. 2008 May 23; 320(5879):1077-81.
[Science. 2008]Curr Biol. 2008 Jul 8; 18(13):R561-3.
[Curr Biol. 2008]Annu Rev Genet. 1989; 23():251-87.
[Annu Rev Genet. 1989]Curr Biol. 2006 Mar 21; 16(6):580-5.
[Curr Biol. 2006]Trends Genet. 2007 Jul; 23(7):359-64.
[Trends Genet. 2007]Genome Res. 2007 Dec; 17(12):1837-49.
[Genome Res. 2007]Curr Genet. 2006 Aug; 50(2):81-99.
[Curr Genet. 2006]BMC Evol Biol. 2008 Mar 25; 8():92.
[BMC Evol Biol. 2008]Annu Rev Genet. 2007; 41():305-30.
[Annu Rev Genet. 2007]Trends Plant Sci. 2006 Mar; 11(3):142-51.
[Trends Plant Sci. 2006]Nat Biotechnol. 2007 Nov; 25(11):1231-2.
[Nat Biotechnol. 2007]Genome Biol. 2008 Jan 17; 9(1):R10.
[Genome Biol. 2008]Nature. 2006 Oct 26; 443(7114):931-49.
[Nature. 2006]Genome Biol. 2008 Jan 17; 9(1):R10.
[Genome Biol. 2008]Nat Biotechnol. 2007 Nov; 25(11):1322-6.
[Nat Biotechnol. 2007]Nat Biotechnol. 2007 Nov; 25(11):1307-13.
[Nat Biotechnol. 2007]Annu Rev Genet. 2007; 41():305-30.
[Annu Rev Genet. 2007]Cell. 2007 Aug 10; 130(3):413-26.
[Cell. 2007]Science. 2006 Jul 7; 313(5783):68-71.
[Science. 2006]Nature. 2006 Oct 26; 443(7114):931-49.
[Nature. 2006]Genome Biol. 2008 Jan 17; 9(1):R10.
[Genome Biol. 2008]Genome Biol. 2008; 9(2):210.
[Genome Biol. 2008]Nat Rev Mol Cell Biol. 2008 Jan; 9(1):22-32.
[Nat Rev Mol Cell Biol. 2008]BMC Evol Biol. 2008 Mar 25; 8():92.
[BMC Evol Biol. 2008]RNA. 2008 May; 14(5):829-35.
[RNA. 2008]Cell. 2006 Nov 17; 127(4):747-57.
[Cell. 2006]Nat Genet. 2002 Dec; 32(4):569-77.
[Nat Genet. 2002]Genetics. 1991 Feb; 127(2):345-53.
[Genetics. 1991]Nature. 2000 Sep 21; 407(6802):386-90.
[Nature. 2000]Nature. 2004 Sep 16; 431(7006):356-63.
[Nature. 2004]Cell. 2007 Aug 10; 130(3):413-26.
[Cell. 2007]Trends Genet. 2007 Jul; 23(7):359-64.
[Trends Genet. 2007]Annu Rev Genet. 1989; 23():251-87.
[Annu Rev Genet. 1989]Proc Natl Acad Sci U S A. 2005 Jan 4; 102(1):15-9.
[Proc Natl Acad Sci U S A. 2005]Cell Microbiol. 2006 May; 8(5):880-9.
[Cell Microbiol. 2006]J Virol. 2000 Jan; 74(2):710-20.
[J Virol. 2000]Mol Plant Microbe Interact. 2006 Jun; 19(6):614-24.
[Mol Plant Microbe Interact. 2006]Proc Natl Acad Sci U S A. 1994 Feb 15; 91(4):1285-9.
[Proc Natl Acad Sci U S A. 1994]J Gen Virol. 1997 Sep; 78 ( Pt 9)():2379-88.
[J Gen Virol. 1997]Genes Dev. 2005 Jul 15; 19(14):1680-5.
[Genes Dev. 2005]Curr Biol. 2007 Mar 20; 17(6):539-44.
[Curr Biol. 2007]Mol Cell. 2008 Jul 11; 31(1):67-78.
[Mol Cell. 2008]Science. 2006 Jul 21; 313(5785):320-4.
[Science. 2006]Science. 2007 Nov 2; 318(5851):761-4.
[Science. 2007]Development. 2008 Jan; 135(1):3-9.
[Development. 2008]Nature. 2007 May 24; 447(7143):399-406.
[Nature. 2007]Curr Biol. 2008 Jun 3; 18(11):795-802.
[Curr Biol. 2008]Nature. 2008 Jun 5; 453(7196):729-31.
[Nature. 2008]Mol Biol Evol. 1985 Mar; 2(2):150-74.
[Mol Biol Evol. 1985]Curr Biol. 2006 Mar 21; 16(6):580-5.
[Curr Biol. 2006]Nature. 2002 Feb 28; 415(6875):1022-4.
[Nature. 2002]Curr Biol. 2006 Mar 21; 16(6):580-5.
[Curr Biol. 2006]Nature. 1991 Jun 20; 351(6328):652-4.
[Nature. 1991]Nature. 2006 Oct 26; 443(7114):931-49.
[Nature. 2006]Nat Biotechnol. 2007 Nov; 25(11):1231-2.
[Nat Biotechnol. 2007]Nature. 2006 Nov 2; 444(7115):85-8.
[Nature. 2006]Nature. 2006 Feb 23; 439(7079):965-8.
[Nature. 2006]BMC Evol Biol. 2007 Jan 10; 7():1.
[BMC Evol Biol. 2007]